Literature DB >> 19740264

Clinical significance of non-diagnostic pathology results from percutaneous transthoracic needle lung biopsy: experience of a tertiary hospital without an on-site cytopathologist.

Joo-Won Min1, Sang-Min Lee, Doo Hyun Chung, Jae-Joon Yim, Seok-Chul Yang, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Hee Soon Chung.   

Abstract

BACKGROUND AND
OBJECTIVE: More non-diagnostic pathology results may be reported following transthoracic needle lung biopsy (TTNB) when no on-site cytopathologist is available. This study was conducted to analyse the final outcomes in patients with non-diagnostic pathology results, and the factors related to the adequacy of specimens.
METHODS: The medical records of consecutive patients who had undergone TTNB from January 2004 to January 2005 were retrospectively analysed. Non-diagnostic pathology results were classified into three groups: (i) atypical cells, (ii) non-specific inflammation and (iii) inadequate specimen. The final diagnosis and clinical outcome for each patient were analysed after additional diagnostic studies and clinical follow up.
RESULTS: TTNB was performed on 291 patients. Specimens were adequate in 256 cases. The results were non-diagnostic for 103 patients, and the percentages of atypical cells, non-specific inflammation and inadequate specimen were 15.5% (16/103), 50.5% (52/103) and 40% (35/103), respectively. In 14 patients (87.5%) the diagnosis of atypical cells was confirmed, and in 10 (62.5%) these were due to malignancies. In two patients (3.8%) the lesions reported as non-specific inflammation were eventually confirmed as malignancies. After repeated attempts to confirm their diagnoses, 22 patients (62.9%) with initial reports of inadequate specimen were diagnosed with specific diseases. Specimen adequacy correlated with technical skill, size of the lesion, guidance method and biopsy method.
CONCLUSIONS: Non-diagnostic pathology results from TTNB, in the absence of an on-site cytopathologist, are of value in assessing the clinical probability of malignancy and can be useful in the management of lung lesions. However, many other factors should be considered in patients with inadequate specimens.

Entities:  

Mesh:

Year:  2009        PMID: 19740264     DOI: 10.1111/j.1440-1843.2009.01610.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  5 in total

1.  CT-guided core needle biopsy of the lung in patients with primary malignancy suspected of lung metastasis: 5-year experience from a single institution.

Authors:  Jianbin Zhu; Xianlong Wang; Yaoming Qu; Zhibo Wen
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

2.  Predictors of False-Negative Results from Percutaneous Transthoracic Fine-Needle Aspiration Biopsy: An Observational Study from a Retrospective Cohort.

Authors:  Young Joo Suh; Jae Hoon Lee; Jin Hur; Sae Rom Hong; Dong Jin Im; Yun Jung Kim; Yoo Jin Hong; Hye Jeong Lee; Young Jin Kim; Byoung Wook Choi
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

3.  Non-diagnostic Results of Percutaneous Transthoracic Needle Biopsy: A Meta-analysis.

Authors:  Kum Ju Chae; Hyunsook Hong; Soon Ho Yoon; Seokyung Hahn; Gong Yong Jin; Chang Min Park; Jin Mo Goo
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

Review 4.  2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology.

Authors:  Soon Ho Yoon; Sang Min Lee; Chul Hwan Park; Jong Hyuk Lee; Hyungjin Kim; Kum Ju Chae; Kwang Nam Jin; Kyung Hee Lee; Jung Im Kim; Jung Hee Hong; Eui Jin Hwang; Heekyung Kim; Young Joo Suh; Samina Park; Young Sik Park; Dong Wan Kim; Miyoung Choi; Chang Min Park
Journal:  Korean J Radiol       Date:  2020-11-19       Impact factor: 3.500

5.  Supplementary benefits of CT-guided transthoracic lung aspiration biopsy for core needle biopsy.

Authors:  Jia-Huan He; Jia-Xing Ruan; Ying Lei; Zhi-Dan Hua; Xiang Chen; Da Huang; Cheng-Shui Chen; Xu-Ru Jin
Journal:  Front Microbiol       Date:  2022-09-14       Impact factor: 6.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.